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INTRODUCTION
Breast cancer is one of the leading causes of death in 
women worldwide (1, 2) and is the second most common 
malignancy newly diagnosed in Korean women. More than 
15000 women were newly diagnosed with breast cancer 
in 2011, and breast cancer was in second (21.5%) place 
among all newly diagnosed cancers in Korean women (www.
ncc.re.kr). Moreover, the 5-year survival rate of breast 
cancer has increased from 83.2% to 91.3% over the last 10 
years due to advances in postoperative treatment modalities 
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and medications. The overall incidence of breast cancer in 
Korean women has increased from 1999 to 2011, and the 
prevalence of breast cancer during this period is 19.3% of 
all cancers in women (3), which agrees with reports on the 
Western population (1, 4). As the number of breast cancer 
survivors increases, patient management and surveillance 
after primary treatment has come under the spotlight. 
Women who have been treated for breast cancer are at 
risk for second breast cancers, such as tumor recurrence in 
the ipsilateral breast or a newly developed cancer in the 
contralateral breast (2, 4, 5). Reported risks for locoregional 
tumor recurrence range from 5–27%, whereas the risk 
for development of contralateral breast cancer is 5–10%, 
with a two six-fold increased risk (4, 6-10). In addition, 
recent studies have demonstrated that local recurrence is 
an independent predictor of survival, an high relative risks 
for developing distant metastases or breast cancer-related 
deaths in patients with local recurrences have been shown 
when compared to patients without a recurrence (10). 
Considering these risks, a well-designed, evidence-
based post-treatment surveillance protocol is needed to 
manage patients with breast cancer after their primary 
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(Table 1) (1, 11, 20). As mammography enables detection 
of an early asymptomatic recurrence, early intervention 
or treatment is also possible (Fig. 1) (9, 21, 22). Several 
recent studies have demonstrated that early detection of a 
recurrence in asymptomatic patients during post-treatment 
follow-up improves survival (4, 22, 23), supporting the role 
of routine mammography for post-treatment surveillance 
of breast cancer. Based on a literature review, Houssami 
and Ciatto (4) reported that the proportion of ipsilateral 
breast recurrences detected on mammography is 50–80%, 
and mammography detects 45–90% of contralateral 
metachronous breast cancers. Paszat et al. (22) reported 
that surveillance mammography is associated with a 
significant reduction in the hazard for death related 
to breast cancer. Similarly, surveillance mammography 
helps detect asymptomatic tumor recurrence, resulting 
in improved patient survival, but most recommendations 
are based on consensus rather than evidence supported 
by RCTs. In another study, the proportion of ipsilateral 
breast recurrences detected with mammography was 
8–51% of lesions detected on mammography only, but 
approximately three-fifths of the participating hospitals 
perform mammography surveillance at 6-month intervals 
for 2 to 5 years in patients with breast conservation 
surgery (24). Such semiannual mammographic surveillance 
allows the detection of a significantly higher proportion of 
cancer recurrences at an earlier stage than that of annual 
treatment. The surveillance program would be intended 
to detect second breast cancers at an early stage when 
curative intervention is possible. Up to now, mammography 
has been the only evidence-based imaging modality with 
demonstrated efficiency for detecting asymptomatic 
tumor recurrence or a second breast cancer in women who 
have been treated for primary breast cancer (2, 4, 11-
17). Ultrasonography (US), magnetic resonance imaging 
(MRI) and 18F-fluorodeoxyglucose (FDG) positron emission 
tomography (PET) have been utilized in many institutions 
to increase detection of second cancers at an early stage.
Imaging Modalities
Mammography 
Screening mammography for women with an average 
risk of breast cancer results in early detection of breast 
cancer, leading to reduced mortality and improved patient 
outcome. Many case-controlled or non-randomized 
controlled trial (RCT) studies show a 20–30% reduction in 
breast cancer mortality after screening (18, 19). Hence, we 
assume that women with an elevated risk for breast cancer, 
including those who have already been treated for primary 
breast cancer, may benefit even more from screening 
mammography. 
At present, mammography is the only imaging modality 
commonly recommended for breast cancer surveillance 
Table 1. Post-Treatment Surveillance Recommendations for Women Treated for Primary Breast Cancer 
Year History & Physical Examinations Mammography Other Studies
American Society  
  of Clinical  
  Oncology  
  (11, 58)
2012
Every 3–6 months for first 3  
  years
Every 6–12 months for years 4–5
Annual follow-up thereafter
Posttreatment mammography  
  1 year after initial mammography
At least 6 months after completion 
  of radiation therapy
Yearly mammography evaluation,  
  unless otherwise indicated
Chest radiography, bone scans, liver  
  US, CT, PET, MRI, or other laboratory  
  tests: not recommended in otherwise  
  asymptomatic patient with no specific  
  findings on clinical examinations
National  
  Comprehensive  
  Cancer Network 
2013
Every 4–6 months for 5 years,  
  then annually
Mammography every 12 months
MRI considered in women with lifetime  
  risk of second primary breast cancer  
  greater than 20%
Other tests not recommended
European Society  
  of Medical  
  Oncology (1)
2013
Every 3–4 months for first 2  
  years
Every 6 months from year 3–5
Annual follow-up thereafter
Ipsilateral (after BCS) &  
  contralateral mammography  
  every 1–2 years
MRI may be indicated for young women  
  with dense breasts, genetic or familial  
  predispositions
Other laboratory or imaging tests not  
  recommended in asymptomatic patients
National Institute 
  for Clinical  
  Excellence 
2011
Regular check-up, determined  
  by physician or patient
Annual mammography 
Other additional studies not routinely  
  recommended
Note.— BCS = breast conserving surgery, CT = computed tomography, MRI = magnetic resonance imaging, PET = positron emission 
tomography, US = ultrasonography
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surveillance (25). However, these results do not support 
establishing intensive surveillance because no significant 
differences was found in tumor size or nodal status between 
the semiannual surveillance and the annual surveillance 
groups, and the follow-up intervals were 3–18 months, 
which was too long to strictly separate the patients into 
two groups (26). As seen in the various reports mentioned 
above, although most studies include mammography for 
post-treatment surveillance of women who have been 
treated for breast cancer, two important issues remain 
unsolved. The mammography follow-up interval and the 
follow-up duration need to be defined. The more popular 
post-treatment surveillance recommendations for patients 
with breast cancer are summarized in Table 1. The American 
Society of Clinical Oncology Clinical Practice Guidelines 
recommend a post-treatment mammogram 1 year after 
initial diagnosis or at least 6 months after completion 
of radiation therapy, and yearly mammography follow-
up thereafter (11). Similarly, the National Comprehensive 
Cancer Network (www.nccn.org, version 2013.03) and 
the National Institute for Clinical Excellence guidelines 
(www.nice.org.uk, 2011) recommend mammography every 
12 months in addition to routine history and physical 
examinations obtained at regular visits. As in the prior 
recommendations, we agree that annual mammography 
should be performed for 5 years after treatment, and 
a mammography every 1–2 years thereafter may be a 
reasonable compromise. 
It should be emphasized that there is insufficient 
evidence regarding mammography follow-up intervals in 
post-treatment surveillance. Additionally, quantifying the 
actual impact of screening mammography in these patients 
excluding bias, specifically lead-time and length-time bias, 
is difficult using mostly non-randomized retrospective 
studies. RCTs are the most appropriate method to estimate 
the effect of early detection of ipsilateral or contralateral 
breast cancer recurrence, but applying this study design to 
clinical practice is not feasible or ethical, as patients who 
have been treated for breast cancer are already at high risk 
for developing second breast cancers. Further prospective 
investigation that includes a large data set showing how 
women with a personal breast cancer history benefit from 
surveillance mammography is anticipated in the future, 
along with evidence-based meticulous screening programs 
that will build on the results. 
Breast Ultrasonography
Ultrasonography is a widely available, relatively 
inexpensive imaging method that is easy to perform, 
has no radiation hazards, does not require a contrast 
agent, and enables biopsy under image guidance. Breast 
US has been popularly used to characterize lesions and 
differentially diagnose breast masses as an adjunctive tool 
to mammography, particularly in women with dense breasts 
(5, 27). Preoperative bilateral whole-breast US also provides 
complementary information to mammography (28, 29), and 
detects up to 88% of contralateral synchronous cancers, 
among which 43% are occult on a mammogram (28). 
Fig. 1. 41-year-old woman who had undergone right partial mastectomy due to invasive ductal carcinoma. 
Follow-up mammography (A) performed 26 months after surgery revealed mass (arrows) at mastectomy site, which was more prominent compared 
to follow-up mammography performed 6 months before. Ultrasonography (B) showed 15-mm mass in right upper outer breast correlating to mass 
detected on mammography. Breast magnetic resonance imaging (C) showed peripherally enhanced mass in right breast (arrows). Subsequent 
biopsy and surgery were performed and revealed invasive ductal carcinoma. 
A CB
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Based on the results of preoperative US, one study showed 
that approximately 16% of women who had undergone 
preoperative US had changes in treatment plans set by 
mammography alone (29). 
Moreover, US has drawn attention as a useful surveillance 
imaging method in addition to mammography in women 
who have been treated for breast cancer. US detects 
ipsilateral recurrent or contralateral metachronous breast 
cancers with higher sensitivity (91–97%) (Table 2) than 
that of palpation or mammography, which have sensitivity 
values of 45.5–79% and 45–87%, respectively (5, 8, 28, 30-
32). Adding US to mammography in the American College 
of Radiology Imaging Network (ACRIN) 6666 trials yielded 
an additional 1.1–7.2 cancers per 1000 high-risk women, 
of which 53% of the 2637 enrolled women had a personal 
history of breast cancer (27). Other than the breast, US is 
an excellent modality to evaluate chest wall and axillary 
areas, which cannot be easily approached by mammography. 
One of the most common sites for post-treatment breast 
cancer recurrence is the chest wall (Fig. 2), either from 
direct extension of the tumor, indirect extension via 
interpectoral nodes, or from undissected lymphatics (32). 
Approximately 10–35% of patients who have been treated 
for breast cancer have a metastasis in the axillary, internal 
mammary, and supraclavicular nodes (33, 34). Among the 
occult regional recurrences after surgical treatment for 
Fig. 2. 44-year-old woman who had undergone modified radical mastectomy of left breast due to invasive ductal carcinoma. 
Ultrasonography (US) performed 30 months after surgery (A) revealed 11-mm hypoechoic lesion located within skin layer (arrow). US-guided fine 
needle aspiration was performed on this lesion, and cytology result was positive for metastatic carcinoma from breast. Breast magnetic resonance 
imaging (B) showed enhanced nodule in left chest wall (arrow) correlating to proven malignant mass. 
A B
Table 2. Diagnostic Performances of Mammography, Ultrasonography, and MRI in Post-Treatment Surveillance of Breast Cancer 
Patients
Mammography Ultrasonography
MRI
Ipsilateral Contralateral Ipsilateral Contralateral
Sensitivity 8–72.7% 8.2–90% 43–91% 94–100% 75–100%
Specificity 61.1–95.5% 31–95.1% 99.0% 66.6–93%
PPV 14.7% 8.6–26.3% 25.0%
NPV 99.2% 99.2–99.5% 100.0%
Accuracy 95.0% 
References (4, 6, 8, 25, 27, 31, 58) (5, 6, 14) (8, 14, 25, 27, 31, 41, 58) (5, 40) (14, 25, 27, 31, 52, 58)
Note.— NPV = negative predictive value, PPV = positive predictive value
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breast cancer, only 21.4% occur at the axillary area lateral 
to the pectoralis muscle, which may be included within the 
fields of mammography and surgical sampling, while the 
remaining 78.6% of regional recurrence was detected by 
US alone at areas other than the axilla (34-36). In other 
studies, the sensitivity of mammography is only 10% (0.0–
14.3%), whereas that of US was around 90% (81.1–100.0%) 
to detect regional or locoregional recurrences (24, 34, 37-
40). 
Several studies have shown surveillance results of US 
applied to women who were treated for breast cancer 
(34, 37, 39-41). The reported cancer detection rates were 
1.7–5.1% per patient, and the positive predictive value 
(PPV) was 21.5–52.6%, with percentages varying according 
to the area involved. Because isolated recurrences are 
associated with distant metastasis and/or poor outcome, 
early detection and targeted treatment for recurrences are 
critical to improve patient outcome (41-43). Early detection 
of a locoregional recurrence of breast cancer after primary 
treatment by US can help guide patient management by 
sorting out those who may benefit by early therapeutic 
intervention or curative treatment of local disease. Patients 
who received a mastectomy and who had a locoregional 
recurrence detected at an early stage or an isolated 
regional recurrence had better survival with short follow-
up (23, 29, 41), but controversy remains about whether 
post-treatment surveillance US actually affects long term 
survival in patients with breast cancer (40) and whether all 
asymptomatic regional recurrences will be detected by US or 
by PET-CT or another imaging modality in clinical practice 
(42). 
One important point to discuss is which patients should 
be recommended for US surveillance. Many studies agree 
that mammography is the basic imaging modality for 
breast cancer surveillance (5), and the usefulness of US 
surveillance can be amplified under conditions in which 
the benefits of mammographic surveillance are reduced 
such as in dense breasts. The sensitivity of US for detecting 
metachronous breast cancer is 94%, regardless of breast 
density, whereas sensitivity of mammography in women 
with dense breasts is lower than that of women with 
scattered fibroglandular tissue (73% vs. 80%) (5). In 
contrast, results of another study show that the differences 
in sensitivity between mammography and US for non-
palpable second breast cancers is not noticeably different 
for ipsilateral breast tumor recurrence (14%) compared to 
that of contralateral breast recurrence (28%), and that the 
sensitivity of US for non-palpable breast tumor recurrences 
drops by about 10% in the ipsilateral breast, which may 
due to sonographically architectural distortion obscuring 
detection of an ipsilateral breast tumor recurrence (38). 
Additionally, the main shortcoming of US in the ACRIN 6666 
trial was the substantial false-positive rate; the PPV of the 
biopsy recommendation after US examinations was < 10.0%. 
However, after reviewing other reports of investigators 
performing sequential US, the PPV was approximately 41% 
(18 of 44 lesions) in the contralateral breast (32) and 67% 
in bilateral breasts (34). As seen in the heterogeneous 
results from prior studies, although US may have its strong 
points for visualizing areas that cannot be approached by 
mammography or provide additional information regarding 
differentiation between postoperative changes and 
locoregional recurrence, little evidence suggests whether US 
is effective and beneficial for improving survival of patients 
with breast cancer and the role of US in post-treatment 
surveillance programs has yet to be investigated.
 
Breast Magnetic Resonance Imaging 
Breast MRI is an important supplementary imaging 
modality to conventional breast cancer evaluation methods, 
particularly for preoperative planning due to its high 
sensitivity (95–100%) in disease detection (44-46), among 
which the amount of glandular density does not have 
an influence. The reported sensitivity of breast MRI for 
detecting tumors in high risk women is significantly higher 
than that of mammography (77–100%), and specificity 
in an acceptable range of 81–95% (45-47). However, the 
women included in these studies were high risk, has a 
strong family history of breast cancer, or were suspected or 
tested to have breast cancer susceptibility genes, such as 
the BRCA mutations. Although breast MRI is recommended 
for screening in women with a lifetime breast cancer risk > 
20–25% by the American Cancer Society (20), the American 
College of Radiology (47), and the Society of Breast 
Imaging (48), these recommendations only state that MRI 
“may be considered” for women who have a personal history 
of breast cancer; that is, women with intermediate risk 
(lifetime breast cancer risk > 15–20%) for breast cancer (47). 
Therefore, little is known about the role of breast MRI in 
post-treatment surveillance programs. 
Breast MRI shows high sensitivity and specificity 
for differentiating between post-treatment changes in 
the breast from recurrent malignancies (Table 2) (31, 
49), particularly when performed later than 12 months 
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after treatment (50). In a study by Brennan et al. (49), 
breast screening with MRI detected cancer in 12% of 
the study population, including women with a personal 
history of breast cancer only, and the PPV of the biopsy 
recommendations from MRI was acceptable at 39%. Based 
on their results, the authors claimed that MRI screening of 
women with a personal history of breast cancer is clinically 
valuable because cancers discovered from screening MRI 
benefit from early detection, as more than half were 
minimal breast cancers (49). This and the results of another 
study by Morris et al. (51) emphasize the importance of a 
personal history of breast cancer treatment as an indication 
for MRI screening. The PPV of biopsy recommendations 
based on MRI features is 32% in women with a family 
history of breast cancer and it increases to 50% in women 
who have also been diagnosed and treated for breast cancer 
(51). Breast MRI screening has the highest yield in women 
with both a family and personal history of breast cancer, 
particularly in those who have had breast conservation 
surgery (51). Additionally, high negative predictive values 
of breast MRI have been reported in women who had breast 
conservation therapy; Belli et al. (31) concluded that 
the absence of enhancing foci in post-treatment breasts 
has 100% reliability for predicting the absence of tumor 
recurrence. There may be no need for additional invasive 
procedures such as biopsy if there are no enhancing foci 
by correlating lesions that are suspected to be recurrences 
on conventional imaging modalities to breast MRI. Patients 
may benefit from screening MRI, with its high NPV, by 
reducing many benign biopsies, which is supported by the 
results of another study (52) concluding that a negative 
MRI is more useful and conclusive than a positive MRI, as 
positive features warrant further investigation. This is also 
supported by a recent study that included a large proportion 
of women who had been treated for breast cancer with 
additionally detected early stage breast cancers on 
supplemental screening breast MRI performed in addition to 
mammography and US; 14.7 more cancers per 1000 women 
were additionally detected by MRI (25). 
MRI for surveillance or screening purposes is limited, 
as this imaging method is expensive, lacks availability, 
requires contrast media injection for adequate imaging, and 
neither the technique nor interpretive criteria for breast 
MRI are standardized (51). Despite its shortcomings, breast 
MRI is a highly sensitive imaging modality. However, when 
and in which circumstances screening breast MRI should 
be applied is still a question for women who have been 
treated for breast cancer. As most postoperative women 
undergoing surveillance are under a hormonal therapy 
that suppresses the ovary, use of MRI is supported in 
postoperative surveillance programs. As in the many studies 
on mammography or US, studies evaluating the efficacy of 
MRI for post-treatment surveillance in women who have 
been treated for breast cancer are of retrospective design 
and include a limited number of patients. Therefore, further 
randomized prospective studies are needed to properly 
assess the role of breast MRI in post-treatment surveillance 
programs. 
Postoperative Surveillance with FDG-PET/CT 
Positron emission tomography/CT has been used for 
preoperative staging and the treatment response of patients 
with breast cancer. This hybrid imaging method has a strong 
point as it enables anatomic localization of the PET signal 
via CT (53). PET/CT is particularly useful in patients who 
are suspected to have or who are exhibiting a recurrence 
on physical examination or conventional imaging methods 
(53, 54). Because PET/CT is highly sensitive for detecting 
lesions and determining whether a recurrence is solitary 
or disseminated, information gained from PET/CT has a 
significant impact on the decision for upcoming treatment 
and post-treatment patient outcome. Sensitivity of PET/CT 
for detecting locoregional recurrence or metastasis among 
patients with breast cancer is approximately 97%, with a 
diagnostic accuracy of 95% in one study (55), supporting 
the efficacy of PET/CT for patients diagnosed or suspected 
of having recurrent breast cancer (Fig. 3). However, there 
is a lack of evidence demonstrating the efficacy and cost-
effectiveness of this modality, along with the hazard of 
radiation exposure and the absence of specific clinical 
indications (56). 
Surveillance for Distant Metastasis: Present 
Status and Future Prospects
Current post-treatment surveillance guidelines for 
patients with treated breast cancer do not recommend 
intensive surveillance, such as routine chest radiography, 
bone scans, or laboratory tests, to evaluate distant 
recurrence or metastatic diseases. Studies have reported 
prolonged survival in patients who had asymptomatic 
metastatic lesions detected at an early stage but early 
detection was not advantageous to patient survival when 
the time of initial breast cancer diagnosis was applied. In 
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other words, lead-time bias or length-time bias may have 
misled thinking that these intensive surveillance programs 
may prolong patient survival (57). Nevertheless, post-
treatment surveillance programs applied to patients with 
breast cancer vary among organizations and countries, 
mostly due to the lack of a standardized protocol, and 
studies evaluating distant metastasis are quite often 
performed along with mammography and physical 
examinations. A recent study based on the Texas Cancer 
Registry (56) represents the current status of imaging 
modalities in post-treatment surveillance programs; only 
55.3% of patients treated for breast cancer showed strict 
adherence to the current surveillance program, including 
a routine physical examination and mammography. During 
the 2001–2007 study period, use of mammography and 
bone scans decreased (81% to 75% and 21% to 13%, 
respectively), whereas use of MRI and PET-CT increased 
significantly (0.5% to 7.0% and 2% to 9%, respectively) 
(56). Based on their report, it is evident that clinicians 
and patients do not feel that the current surveillance 
Fig. 3. 63-year-old woman who had undergone left mastectomy due to invasive ductal carcinoma. 
Negative findings were seen on follow-up mammography and ultrasonography performed for surveillance. Follow-up positron emission 
tomography-computed tomography scan (A, arrows) performed 38 months later for surveillance revealed multiple areas of increased 
fluorodeoxyglucose uptake in both lungs, mediastinum, and liver. CT scans revealed multiple metastatic nodules in both lower lungs (B, arrows), 
enlarged metastatic mediastinal lymph nodes (C, arrows), and low-attenuating metastatic mass in caudate lobe of liver (D, arrow). 
A
C
B
D
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program with mammography as the only imaging modality 
is sufficient. Although evidence does not yet demonstrate 
that early detection of a distant metastasis improves 
patient survival, early detection provides a chance for 
curative intervention, which may affect quality of life or 
long-term survival of patients, and this may be the cause 
for the current trend in which supplemental surveillance 
imaging modalities other than just mammography are used. 
However, not all patients benefit from these extensive and 
rather costly studies repeated annually, and the accuracy 
of the additional imaging modalities has not yet been 
confirmed. Additionally, these additional modalities may 
reveal many false-positive lesions, particularly MRI and 
PET scans (20, 54, 55), and may provoke unnecessary 
interventional procedures and patient anxiety. Considering 
the development of new imaging technologies and the 
desire of clinicians and patients for better supplementary 
surveillance methods, it is difficult to insist on patient 
compliance with the current surveillance program. Therefore, 
discrete evidence on the cost-effectiveness and accuracy of 
applying supplemental modalities to mammography in terms 
of patient survival is required when used for post-treatment 
surveillance of breast cancer. 
 
CONCLUSION
Currently, mammography is the single imaging modality 
recommended for routine follow-up surveillance in women 
who have been treated for breast cancer. The role of 
additional imaging modalities, such as US, MRI, and PET-
CT, as post-treatment surveillance in women treated for 
breast cancer has not yet been established, but they are 
potentially useful and show high sensitivity and accuracy 
for detecting recurrences or distant metastases. Although 
many studies have demonstrated the efficacy of these 
additional imaging modalities when applied to post-
treatment surveillance, they are currently used in clinical 
practice without specific clinical indications or organized 
programs due to a lack of concrete evidence. An evaluation 
of the cost-effectiveness of these imaging modalities 
should be considered because of their additional costs. A 
number of different guidelines regarding post-treatment 
surveillance of patients with breast cancer have been 
produced worldwide. This is mostly from efforts to ensure 
that patients should undergo the most appropriate follow-
up to decrease patient morbidity and mortality and enable 
long-term survival after treatment. The heterogeneity 
regarding post-treatment patient management may arise 
from the lack of solid evidence on the potential benefits 
of each follow-up imaging modality. The multiplicity 
of guidelines or recommendations may reflect that 
socioeconomic conditions, mostly financial causes such as 
insurance policies, vary among countries and institutions. 
This is an important matter that should be considered when 
investigating the most appropriate and effective method for 
post-treatment surveillance of patients with breast cancer. 
Further prospective studies including a large number of 
patients are expected in the future to demonstrate the role 
of various imaging modalities in post-treatment surveillance 
programs and how they affect survival in patients treated 
for breast cancer.
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